DENVER, Colo. (247marketnews.com) -- Amir F. Heshmatpour, CEO of NeOnc Technologies Holdings (NASDAQ:NTHI), purchased another 37,000 shares of the company’s common stock, increasing his personal investment following NeOnc’s announcement of a $15 million financing backed by healthcare-focused institutional investors.
A September 14 Form 4 shows that Heshmatpour acquired the shares on September 11 at a weighted-average price of $3.6654 per share, representing approximately $135,620 in additional investment. The purchase continues a previously disclosed pattern of insider buying in NeOnc shares.
The institutional financing, announced September 9, was priced at $4.20 per common share and accompanying warrant, with pre-funded warrants available in lieu of common shares. The offering covers approximately 3.57 million shares or equivalents, along with warrants to purchase another 3.57 million shares at an exercise price of $4.20 per share over a five-year term. NeOnc said it intends to use the net proceeds for working capital, general corporate purposes and the redemption of its Series A convertible preferred stock.
The combination of continued insider buying and institutional backing highlights investor conviction in NeOnc’s efforts to develop new treatments for brain cancer. Heshmatpour is increasing his personal financial commitment as the company advances novel therapies built around its patented NEO technology platform.
The platform is designed to address one of the central challenges in treating brain tumors: delivering therapeutic agents to the brain. NeOnc has exclusively licensed a worldwide portfolio of issued patents and pending applications from the University of Southern California covering NEO100, NEO212 and related technologies. The company reports patent protection extending through 2038.
NEO100 is a patented formulation of highly purified perillyl alcohol administered through the nose and designed to reach the brain along olfactory and trigeminal pathways. In its Phase 2a study, patients self-administered the investigational treatment at home.
On August 12, NeOnc reported positive topline results from the study, which enrolled 24 patients with recurrent or progressive high-grade IDH1-mutant glioma. According to the company’s analysis, six-month progression-free survival was 48.9%, compared with a prespecified historical benchmark of 20%, while median overall survival was reported at 26.09 months.
Behind those numbers are patients and families hoping for more time together. At the August 12 readout, NeOnc reported that one patient had remained progression-free for approximately 19 months, while five of the 24 participants were still receiving treatment.
At-home dosing could add another meaningful dimension to NEO100’s potential value proposition. Administering daily treatment in familiar surroundings may reduce the need for frequent travel to treatment centers and help lessen some of the anxiety associated with repeated medical visits. For patients and caregivers, that could translate into a more manageable treatment routine, less disruption to daily life and more time at home with family—all while remaining under appropriate clinical supervision. NeOnc noted at its August 12 readout that formal quality-of-life analyses were still underway, leaving the potential patient-experience benefits of the delivery model an important area to watch.
The company is also moving to define the regulatory path ahead. Following the positive topline readout, NeOnc said it intended to request a Type B meeting with the FDA to discuss a potential registrational development strategy. “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study,” Heshmatpour said in the company’s August 12 announcement. A constructive regulatory discussion could provide greater clarity on the requirements and timeline for advancing NEO100 toward a potential registrational study.
Meanwhile, NeOnc’s second lead candidate, NEO212, gives investors another way to evaluate the potential of the company’s platform. NEO212 combines perillyl alcohol with temozolomide in an oral molecule designed to improve delivery across the blood-brain barrier. In its June 16 update, NeOnc reported completing Phase 1 dose escalation and selecting 610 mg as the recommended Phase 2 dose, positioning the program for its next stage of clinical development.
The broader trajectory is becoming increasingly compelling. Encouraging clinical data, continued purchases by the company’s CEO, fresh institutional capital and multiple advancing therapeutic
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.